Targeting SOX2+ cells in tumor masses with mithramycin, a drug that is highly effective against SOX2+ mouse and human SHH MB cells in vitro, stopped the tumor growth (Figure 3A) (Vanner et al., 2014). Here, SOX2 is linked to neoplasm.